Navigating Novel Allogeneic Immunotherapy Approaches in Hematologic Malignancies

Orca-T improved clinical outcomes both overall and across patient subgroups with varied demographic and clinical features in the Precision-T trial.

Orca-T plus allogeneic CAR T-cell therapy may represent a rational treatment approach in high-risk B-cell malignancies.

Orca-T given with reduced intensity conditioning led to robust myeloid/T-cell engraftment and low rates of acute GVHD in hematologic malignancies.

Myeloablative Orca-Q demonstrated efficacy and safety in high-risk hematologic malignancies.